Ghadimi, Michael B.

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Bernhardt, M."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Koenig, A."],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T10:20:53Z"],["dc.date.available","2018-11-07T10:20:53Z"],["dc.date.issued","2016"],["dc.format.extent","75"],["dc.identifier.isi","000371353700239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41971"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Heterogeneity of KRAS Mutation Status in Rectal Cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","57"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Kauffels, Anne"],["dc.contributor.author","Kitzmüller, Marie"],["dc.contributor.author","Gruber, Andrea"],["dc.contributor.author","Nowack, Hannah"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Kuthning, Anja"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Czejka, Martin"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Sperling, Jens"],["dc.date.accessioned","2020-12-10T14:11:27Z"],["dc.date.available","2020-12-10T14:11:27Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s10585-019-09954-5"],["dc.identifier.eissn","1573-7276"],["dc.identifier.issn","0262-0898"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71079"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.contributor.author","Seufferlein, T."],["dc.contributor.author","Uhl, W."],["dc.contributor.author","Kornmann, M."],["dc.contributor.author","Algül, H."],["dc.contributor.author","Friess, H."],["dc.contributor.author","König, A."],["dc.contributor.author","Ghadimi, M."],["dc.contributor.author","Gallmeier, E."],["dc.contributor.author","Bartsch, D.K."],["dc.contributor.author","Lutz, M.P."],["dc.contributor.author","Ettrich, T.J."],["dc.date.accessioned","2022-11-01T10:17:43Z"],["dc.date.available","2022-11-01T10:17:43Z"],["dc.date.issued","2022"],["dc.description.sponsorship"," http://dx.doi.org/10.13039/100002491 Bristol-Myers Squibb Co"],["dc.identifier.doi","10.1016/j.annonc.2022.09.161"],["dc.identifier.pii","S0923753422041849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/116888"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-605"],["dc.relation.issn","0923-7534"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.volume","72"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Roesler, Birte"],["dc.contributor.author","Bielfeld, Christian"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ried, Thomas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Grade, Marian"],["dc.date.accessioned","2018-11-07T09:11:10Z"],["dc.date.available","2018-11-07T09:11:10Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1158/1538-7445.AM2012-3446"],["dc.identifier.isi","000209701502014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26663"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.publisher.place","Philadelphia"],["dc.title","Stat3 is a potential molecular target for chemoradiosensitization of colorectal cancer cells"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Langenbeck's Archives of Surgery"],["dc.contributor.author","Azizian, Azadeh"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-09-01T09:51:31Z"],["dc.date.available","2022-09-01T09:51:31Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Purpose\n VIPoma belongs to the group of neuroendocrine neoplasms. These tumours are located mostly in the pancreas and produce high levels of vasoactive intestinal peptide (VIP). In most cases, a metastatic state has already been reached at the initial diagnosis, with high levels of VIP leading to a wide spectrum of presenting symptoms. These symptoms include intense diarrhoea and subsequent hypopotassaemia but also cardiac complications, with life-threatening consequences. Treatment options include symptomatic therapy, systemic chemotherapy and targeted therapy, as well as radiation and surgery. Due to the low incidence of VIPoma, there are no prospective studies or evidence-based therapeutic standards to date.\n \n \n Methods\n To evaluate the possible impact of different therapy strategies, we performed literature research using PubMed.\n \n \n Results\n All possible treatment modalities for VIPoma have at least one of two therapy goals: antisecretory effects (symptom control) and antitumoural effects (tumour burden reduction). Symptomatic therapy is the most important in the emergency setting to rehydrate, balance electrolytes and stabilise the patient. Symptomatic therapy is also of great importance perioperatively. Somatostatin analogues play a major role in symptom control, although their efficiency is often limited. Chemotherapy may be effective in reaching stable disease for a certain time period, although its impact on symptom control is limited and often delayed. Among targeted therapy options, the usage of sunitinib appears to be the most effective in terms of symptom control and showing antitumoural effects at the same time. Experience with radiation is still limited; however, local ablative procedures seem to be promising options. Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues (SSAs, 177Lu-DOTATATE) offers a targeted approach, especially in patients with high somatostatin receptor density. Surgery is the first-line therapy for nonmetastatic VIPoma. Additionally, if the resection of all visible tumour lesions is possible, the surgical approach seems preferable to other strategies in highly symptomatic patients. The role of surgery in very advanced stages where only tumour debulking is possible remains debatable. However, a high rate of immediate symptom control can be achieved by tumour debulking followed by somatostatin therapy, although the impact on survival remains unclear.\n \n \n Conclusion\n Surgery is the only curative option for nonmetastatic VIPoma. Additionally, surgery should be a first-line therapy option for highly symptomatic patients, especially if the resection of all tumour lesions (primary tumour and metastasis) is achievable. In frail patients, other modalities can be used."],["dc.identifier.doi","10.1007/s00423-022-02620-7"],["dc.identifier.pii","2620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113988"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1435-2451"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Treatment options of metastatic and nonmetastatic VIPoma: a review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Azizian, A."],["dc.contributor.author","Salendo, Junius"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:44:05Z"],["dc.date.available","2018-11-07T09:44:05Z"],["dc.date.issued","2014"],["dc.format.extent","7"],["dc.identifier.isi","000332306700021"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34318"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Circulating microRNAs to monitor preoperative CRT in rectal cancer patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","227"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Chirurg"],["dc.bibliographiccitation.lastpage","231"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2021-04-14T08:30:43Z"],["dc.date.available","2021-04-14T08:30:43Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00104-020-01345-x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83348"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1433-0385"],["dc.relation.issn","0009-4722"],["dc.title","Personalmanagement und Leadership in der Chirurgie"],["dc.title.translated","Human resources management and leadership in surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1437"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Scandinavian Journal of Gastroenterology"],["dc.bibliographiccitation.lastpage","1439"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Horstmann, Olaf"],["dc.contributor.author","Jacobsen, K."],["dc.contributor.author","Feth, J."],["dc.contributor.author","Becker, H."],["dc.date.accessioned","2018-11-07T09:47:22Z"],["dc.date.available","2018-11-07T09:47:22Z"],["dc.date.issued","2002"],["dc.description.abstract","Background: A single centre study was conducted to examine the frequency of cholecystectomies, both open and laparoscopic, up to 2 years prior to the diagnosis of pancreatic cancer. In particular, it was of interest to investigate whether there is a diagnostic delay in a significant number of pancreatic cancer patients and if these patients already have symptoms or findings at the time of cholecystectomy that might have been indicative of the underlying malignant disease. Methods: It is demonstrated that 17 out of 186 pancreatic cancer patients (9%) underwent a cholecystectomy within the 2 years prior to cancer diagnosis. Results: A significant number of these patients showed a considerable weight loss at the time of the cholecystectomy. It is hypothesized that symptoms which led to cholecystectomies in these patients were most likely related to the pancreatic cancer. Owing to the resulting delay of pancreatic cancer diagnosis the resection rate with curative intent decreases to 35% from 44% in the whole series. Conclusion: Patients suffering from cholecystolithiasis and showing atypical symptoms or other notable findings such as considerable weight loss might be assessed in more detail pre- as well as postoperatively in order to minimize the diagnostic delay in pancreatic cancer and to avoid unnecessary operations."],["dc.identifier.doi","10.1080/003655202762671323"],["dc.identifier.isi","000180223500014"],["dc.identifier.pmid","12523594"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35099"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis As"],["dc.relation.issn","0036-5521"],["dc.title","Delay of diagnosis in pancreatic cancer due to suspected symptomatic cholelithiasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cellular Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Ried, Thomas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Heselmeyer-Haddad, Kerstin"],["dc.contributor.author","Camps, Jordi"],["dc.contributor.author","Hummon, Amanda"],["dc.contributor.author","Emons, Georg"],["dc.contributor.author","Auer, Gert"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Difilippantonio, Michael J."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T11:19:37Z"],["dc.date.available","2018-11-07T11:19:37Z"],["dc.date.issued","2008"],["dc.format.extent","91"],["dc.identifier.isi","000254301100002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55325"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","Meeting of the International-Society-for-Cellular-Oncology (ISCO 2008)"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","1570-5870"],["dc.title","Exploiting the genome and transcriptome for individualized cancer diagnosis and treatment stratification"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]